Share post
by Barbados Pharmaceutical Inc.
St John's, Antigua and Barbuda | 3 November 2026
Barbados and its Nigerian partners, working with the African Export-Import Bank (Afreximbank), are advancing a pharmaceutical manufacturing project with an estimated investment cost of US$ 32 million, strengthening Africa–Caribbean industrial cooperation and regional health security.
The investment is intended to establish an intravenous (IV) fluids manufacturing facility in Barbados, with an initial annual capacity of 12 million units with scope for expansion. Additional pharmaceutical products could follow, subject to technical, commercial and regulatory assessment. The facility will support access to essential products, skilled employment and regional trade.
The proposed IV fluids facility forms part of Barbados’ wider pharmaceutical development programme. The project was advanced through agreements signed during the Commonwealth Heads of Government Meeting (CHOGM) 2026 in Antigua and Barbuda, and will be championed by the Government of Barbados, the Government of the Federal Republic of Nigeria, Barbados Pharmaceutical Inc. (BPI), - AMA Medical Manufacturing (Nigerian pharmaceutical manufacturer) and the African Export–Import Bank (Afreximbank).
The project has received initial support from the World Trade Organisation (WTO), Secretariat who envisions it as a catalyser for trade through enhanced regulatory frameworks for the diversification of the production of essential medical products, including in the Caribbean as well as encouraging South-South and triangular partnerships for growth, development and job creation.
The announcement saw the signing of a memorandum of understanding between BPI and AMA Medical Manufacturing, and a project preparation facility term sheet between AMA and Afreximbank, marking the first step in a proposed comprehensive financing solution for the project.
The proposed financing solution would combine preparation support with senior debt, working capital and risk-bearing instruments to help bring the facility into operation. Production is targeted to commence in 2029.
US$ 32 million
Estimated investment cost
12 million units
Initial annual capacity
2029
Production is targeted to commence
Prime Minister of Barbados, the Honourable Mia Amor Mottley, welcomed the initiative as a step towards economic resilience and practical Africa–Caribbean cooperation.
“Barbados may be a small island state, but our ambitions for our people and our region are not small. This partnership represents the determination of African and Caribbean nations to build productive capacity, strengthen our health security and create opportunities that will endure for generations. It is also a powerful expression of what becomes possible when we recognise our shared history and choose to shape our future together.”
The Honourable Mia Amor MottleyPrime Minister of Barbados
His Excellency Senator George Akume, Commander of the Order of the Niger (CON), Secretary to the Government of the Federation (SGF), Nigeria, emphasised bilateral industrial cooperation.
“Nigeria's partnership with Barbados reflects our commitment to deepening economic cooperation between Africa and the Caribbean through practical industrial initiatives. By bringing together Nigerian manufacturing expertise and Caribbean investment opportunities, we can strengthen healthcare production, expand trade and create new pathways for technology exchange and skills development amplifying the potential of South-South Cooperation.”
His Excellency Senator George AkumeSecretary to the Government of the Federation (SGF), Nigeria
Dr Ngozi Okonjo-Iweala, Director-General of the World Trade Organization (WTO), highlighted the importance of trade, investment, and South-South cooperation in diversifying pharmaceutical supply chains, strengthening health security and creating opportunities for industrial development.
“We are delighted to see this partnership taking shape, and to have been part of the journey. This is re-globalization in action. The COVID-19 pandemic exposed the risks of concentrating essential medical production in too few countries. This partnership demonstrates how trade and investment can help expand production, connect the capabilities of Africa and the Caribbean, and deepen South-South and triangular cooperation. By expanding pharmaceutical manufacturing, it strengthens supply chain resilience while creating new opportunities for growth, development and industrial capacity.”
Dr Ngozi Okonjo-IwealaDirector-General of the World Trade Organization (WTO)
Mr. Denys Denya, Senior Executive Vice-President at Afreximbank, said
“Afreximbank’s partnership with the Caribbean gained momentum during the COVID-19 pandemic, when we worked with African and Caribbean partners to facilitate access to vaccines. That cooperation developed into a broader partnership to turn our shared history into stronger trade, investment and productive capacity across Africa and the Caribbean. This project carries that ambition forward: Nigerian manufacturing expertise and investment in Barbados can help the Caribbean build local production of essential medicines, strengthen health sovereignty, transfer technology and create skilled jobs. Our intention is to provide a comprehensive financing solution, beginning with the Project Preparation Facility and extending to senior debt, working capital and risk-bearing instruments; deepening trade between our regions while helping CARICOM build more resilient medical supply chains.”
Mr. Denys DenyaSenior Executive Vice-President at Afreximbank
The partnership initially focuses on IV fluids, an essential product across healthcare systems.
AMA Medical Manufacturing brings Nigerian manufacturing expertise; BPI is developing a pharmaceutical industry in Barbados serving regional and international markets.
The proposed PPF is the first stage of Afreximbank’s intended financing support. It would support the technical, commercial and financial assessments needed to establish viability, define the financing structure and prepare the project for investment.
Mr. Abdullahi Musa Bello, Chairman of AMA Holdings, highlighted the commercial opportunities presented by the partnership.
“This partnership represents an opportunity to bring established Nigerian manufacturing capabilities into a new market while contributing to the development of pharmaceutical production in the Caribbean. Our focus is on building a commercially viable operation supported by strong technical expertise, reliable supply chains and sustainable market opportunities. We believe that cooperation between African and Caribbean enterprises can create lasting industrial value for both regions. We are grateful to the Governments of Barbados and Nigeria and Afreximbank for making this partnership happen, with the support of the WTO Secretariat.”
Mr. Abdullahi Musa BelloChairman of AMA Holdings
Dr Cindi Lewis, Acting Chief Executive Officer of Barbados Pharmaceutical Inc., emphasised the importance of translating the agreements into practical industrial development.
“For generations, Africa and the Caribbean have shared a history. What excites me about this partnership is the opportunity to build a shared future, one that creates lasting opportunities for our people. AMA brings manufacturing experience and Afreximbank brings project preparation and a holistic financing approach. Our job now is to do the technical and financial work carefully, so that what is agreed in St John's becomes production in Barbados.”
Dr Cindi LewisActing Chief Executive Officer of Barbados Pharmaceutical Inc.
The facility is intended to provide a platform for broader pharmaceutical industrial development, alongside work on skills, regulation, investment and market access.
The initiative builds on existing Barbados–Nigeria trade. AMA’s first IV fluids shipment reached Barbados in March 2026, with further shipments planned for Antigua and Barbuda, the British Virgin Islands and St Lucia.
BPI is also working with AMA-MED and Barbados-based Lenstec to expand opportunities for Barbadian medical technology in Nigeria.
Barbados enacted legislation in June 2026 to establish the Barbados Medical Products Authority; regulatory and institutional implementation is under way.
The manufacturing project now moves through project preparation, feasibility, financing and regulatory processes.
The CHOGM arrangements advance implementation; project financing, regulatory approvals and construction arrangements are not yet fully secured.
Barbados Pharmaceutical Inc. (BPI) and Tudo Bem Tudo Bom USA, LLC (TBTB Pharma) have agreed to work together on regional market intelligence, therapeutic area priorities and commercial routes to market, covering three of the five pillars of BPI’s published sector strategy.
Hiofu and BPI partner to bring verified skills infrastructure to Barbados’ pharmaceutical sector, strengthening workforce visibility and supporting regional manufacturing growth.
BPI and AMA Medical Manufacturing are advancing a joint venture to build an IV fluids facility at the Grantley Adams Industrial Estate, with project preparation launching in fall 2026.